JZL195 is primarily utilized in research settings to study the endocannabinoid system and its role in various physiological processes. It functions as a dual inhibitor of enzymes FAAH and MAGL, which are involved in the breakdown of endocannabinoids. By inhibiting these enzymes, JZL195 increases the levels of endocannabinoids like anandamide and 2-AG, allowing researchers to investigate their effects on pain, inflammation, mood, and neurological disorders. This compound is particularly valuable in preclinical studies aimed at understanding the therapeutic potential of modulating the endocannabinoid system for conditions such as chronic pain, anxiety, and neurodegenerative diseases. Its use is confined to laboratory experiments and is not approved for therapeutic applications in humans.